Mounjaro weight loss: what one coffee and yoghurt actually tells us

What's this video probably claiming?

Based on the caption and hashtags, @20sevenandcounting is documenting a weight loss journey using Mounjaro (tirzepatide), a dual GIP and GLP-1 receptor agonist. The creator appears to be sharing what they ate in a day, specifically two litres of water, a coffee, and a yoghurt, framing this as a typical intake while on the medication. The excitement about "weigh day" strongly implies they're expecting significant results and attributing those results, at least partly, to this reduced calorie pattern. The implicit claim here is that tirzepatide is suppressing appetite to the point where very minimal food feels sufficient, which is consistent with what the drug actually does. The secondary, quieter claim is that this kind of eating pattern is healthy or at least manageable on GLP-1 therapy. That second part deserves more scrutiny than TikTok comment sections tend to give it.

What does the science actually show?

Tirzepatide does produce dramatic appetite suppression. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) showed that at the 15mg dose, participants lost a mean of 20.9% of body weight over 72 weeks, with caloric intake dropping substantially. That appetite reduction is real and well-documented. What the trial did not show is that eating as little as possible accelerates results safely. Protein intake in particular becomes a serious concern when total food volume drops this low. Research by Dillon et al. (2023, Obesity) examining body composition during GLP-1 therapy found that without adequate protein and resistance activity, lean muscle mass loss can account for a disproportionate share of total weight lost. Two litres of water is sensible. One coffee and a yoghurt as apparent daily nutrition is not a clinical recommendation, it is an anecdote that happens to align with the drug's side effect profile.

Where does the social media noise diverge from clinical reality?

The problem with this style of content, and there are tens of thousands of similar videos, is that it conflates medication-induced appetite suppression with a sustainable eating strategy. On TikTok, barely eating while on Mounjaro gets framed as a personality trait or a win rather than a potential clinical flag. Physicians prescribing tirzepatide are generally advising patients to hit protein targets of around 1.2 to 1.6 grams per kilogram of body weight daily, based on guidance from obesity medicine specialists including recommendations discussed in Apovian et al. (2015, Journal of Clinical Endocrinology and Metabolism). A single yoghurt does not get anyone close to that. There is also growing concern, raised in papers like Wilding et al. (2022, Diabetes, Obesity and Metabolism), about micronutrient deficiencies in patients who significantly restrict intake without structured dietary support. The scale going down is not the whole story.

What should you actually know?

If you are on tirzepatide or any GLP-1 therapy and finding it hard to eat, that is the drug working as intended, but it does not mean you should eat as little as possible. The clinical consensus is that the quality and composition of what you do eat matters more, not less, when total volume drops. Prioritise protein at every meal, even small ones. Consider speaking with a dietitian experienced in GLP-1 management. The excitement around weigh day is understandable, and the weight loss on these medications is often genuinely impressive. But videos like this one, watched by nearly 30,000 people, normalise very low intake without any of the nutritional context that a prescribing clinician would insist on. Progress on the scale is not automatically a sign that everything is going well internally. Muscle mass, micronutrient status, and long-term metabolic health are not visible in a weigh-in clip.